NASDAQ:UBX - Unity Biotechnology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.67
  • Forecasted Upside: 230.46 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.32
▼ -0.05 (-2.11%)

This chart shows the closing price for UBX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Unity Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UBX

Analyst Price Target is $7.67
▲ +230.46% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Unity Biotechnology in the last 3 months. The average price target is $7.67, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 230.46% upside from the last price of $2.32.

This chart shows the closing price for UBX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Unity Biotechnology. This rating has held steady since July 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/6/2021HC WainwrightReiterated RatingBuy$12.00Medium
7/28/2021HC WainwrightReiterated RatingBuy$12.00High
6/28/2021CitigroupUpgradeSell ➝ BuyHigh
6/7/2021HC WainwrightInitiated CoverageBuy$12.00Low
3/26/2021MizuhoBoost Price TargetNeutral$4.00 ➝ $5.00High
2/16/2021CitigroupDowngradeNeutral ➝ Sell$5.00 ➝ $6.00Low
8/24/2020MizuhoReiterated RatingBuyHigh
8/18/2020The Goldman Sachs GroupLower Price TargetNeutral$8.00 ➝ $4.00High
8/18/2020CitigroupDowngradeBuy ➝ Neutral$31.00 ➝ $5.00High
8/18/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$13.00 ➝ $5.00High
8/17/2020MizuhoDowngradeBuy ➝ Neutral$33.00 ➝ $4.00High
8/17/2020Roth CapitalDowngradeBuy ➝ Neutral$35.00 ➝ $4.00High
7/27/2020Roth CapitalInitiated CoverageBuy$35.00High
4/15/2020Morgan StanleyLower Price TargetOverweight$14.00 ➝ $13.00Low
12/12/2019Cantor FitzgeraldReiterated RatingOverweight$20.00High
11/18/2019MizuhoReiterated RatingBuy$33.00Medium
10/17/2019Cantor FitzgeraldReiterated RatingOverweightLow
7/15/2019Morgan StanleySet Price TargetBuy$14.00Medium
3/6/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$21.00High
3/6/2019MizuhoReiterated RatingBuyHigh
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$25.00 ➝ $24.00High
9/6/2018MizuhoInitiated CoverageBuy ➝ Buy$33.00Medium
5/29/2018CitigroupInitiated CoverageBuy$32.00High
5/29/2018Morgan StanleyInitiated CoverageOverweight$25.00High
5/29/2018The Goldman Sachs GroupInitiated CoverageNeutral$17.00High
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/20/2021

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Unity Biotechnology logo
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in Brisbane, CA.
Read More

Today's Range

Now: $2.32
Low: $2.26
High: $2.39

50 Day Range

MA: $3.03
Low: $2.31
High: $3.74

52 Week Range

Now: $2.32
Low: $2.23
High: $9.78

Volume

354,150 shs

Average Volume

557,806 shs

Market Capitalization

$127.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Unity Biotechnology?

The following Wall Street analysts have issued stock ratings on Unity Biotechnology in the last twelve months: Citigroup Inc., HC Wainwright, Mizuho, and Zacks Investment Research.
View the latest analyst ratings for UBX.

What is the current price target for Unity Biotechnology?

3 Wall Street analysts have set twelve-month price targets for Unity Biotechnology in the last year. Their average twelve-month price target is $7.67, suggesting a possible upside of 223.5%. HC Wainwright has the highest price target set, predicting UBX will reach $12.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $5.00 for Unity Biotechnology in the next year.
View the latest price targets for UBX.

What is the current consensus analyst rating for Unity Biotechnology?

Unity Biotechnology currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UBX will outperform the market and that investors should add to their positions of Unity Biotechnology.
View the latest ratings for UBX.

What other companies compete with Unity Biotechnology?

Other companies that are similar to Unity Biotechnology include Scopus BioPharma, Asian Citrus, CUE Energy Resources, Graphene NanoChem, Inova Resources Limited, and Mawson Infrastructure Group.

How do I contact Unity Biotechnology's investor relations team?

The company's listed phone number is (650) 416-1192. The official website for Unity Biotechnology is www.unitybiotechnology.com.